NCT02845713View on ClinicalTrials.gov

Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 17, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 4, 2016

Conditions
Wuchereria Bancrofti Infection
Interventions
DRUG

Ivermectin, Diethylcarbamazine Albendazole (IDA)

To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)

Trial Locations (1)

Unknown

Agboville District Hospital, Agbobille

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

lead

University Hospitals Cleveland Medical Center

OTHER

NCT02845713 - Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) | Biotech Hunter | Biotech Hunter